Retnakaran R, et al. - The experts embraced this study to assess the impact on beta-cell function over 2-years of two approaches to maintenance therapy [intermittent short-term intensive insulin therapy (IIT) every 3-months vs daily metformin] in early type 2 diabetes (T2DM). For maintaining beta-cell function and glycemic control over 2-years, metformin (following induction IIT) was superior to intermittent IIT. In early T2DM, an exploration of the strategy of induction and maintenance therapy was recommended in order to preserve beta-cell function.